Clinical trial Recruiting at 1 site Observational Ages 18 and up

Monocyte HLA-DR monitoring to detect immune weakness in severe intra-abdominal infections at risk for fungal invasion

Official title: Evaluation of the Innate Immune Response Through Monocyte HLA-DR Monitoring During Severe Intra-abdominal Candidiasis in the Critically Ill Patients

Run by Central Hospital, Nancy, France · NCT07130799 · Data updated 2026-11-12

This will test whether measuring monocyte HLA-DR can reveal innate immune weakness in adult ICU patients with severe intra‑abdominal infections who are at risk for invasive Candida.

More Sepsis trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorCentral Hospital, Nancy, France
Academic / other
Locations1 site (Vandœuvre-lès-Nancy)
StatusRecruiting
StartedNovember 14, 2025
Main results expectedSeptember 1, 2026
Study endsMarch 1, 2027
Registry record updatedFebruary 9, 2026
Trial IDNCT07130799 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) admitted to ICU or intermediate care for severe intra‑abdominal infection requiring urgent abdominal surgery who have one or more risk factors for intra‑abdominal candidiasis or a high peritonitis score are ideal candidates.

Probably not a fit

Patients who are not critically ill, managed without surgery (e.g., radiologic drainage only), moribund with expected imminent death, or those without risk factors for intra‑abdominal candidiasis are unlikely to gain direct benefit from this observational monitoring.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational immunomonitoring protocol enrolling adult ICU patients undergoing urgent surgery for severe intra‑abdominal infection and at least one risk factor for intra‑abdominal candidiasis. Blood samples will be taken to measure monocyte HLA‑DR expression as a marker of innate immune function and compared between patients who develop intra‑abdominal candidiasis and those with severe bacterial intra‑abdominal infections. The aim is to determine whether a deeper or more prolonged drop in HLA‑DR is associated with invasive fungal infection, which could inform earlier risk stratification. No investigational drug is given; the study uses laboratory immune profiling alongside routine clinical care.

Why it matters

Potential benefit: If successful, the findings could enable earlier identification of patients at high risk for invasive Candida and guide more timely antifungal or supportive interventions.

How similar studies have gone: Previous critical‑care studies have shown that low monocyte HLA‑DR correlates with immune suppression and worse outcomes in sepsis, but its specific predictive value for intra‑abdominal candidiasis remains incompletely validated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patient (≥ 18 years old)
* Patient admitted to the ICU or intermediate care unit for a severe intra-abdominal infection requiring urgent abdominal surgery
* Presence of at least one risk factor for intra-abdominal candidiasis:

  * Abdominal surgery within the last 7 days
  * Supramesocolic gastrointestinal perforation
  * Healthcare-associated intra-abdominal infection
  * Community-acquired intra-abdominal infection in an immunocompromised patient\*
  * Intra-abdominal infection complicated by septic shock
  * Broad-spectrum antibiotic exposure within 72 hours prior to surgery
* And/or a Peritonitis Score ≥ 3 out of 4
* Patient affiliated with or benefiting from a national health insurance system
* Patient who has received full information about the clinical study

Exclusion Criteria:

* Radiologically guided drainage without surgery
* Infected acute pancreatitis
* Limitation or withdrawal of life-sustaining treatments
* Moribund patient with an expected life expectancy \< 48 hours
* Woman of childbearing potential without effective contraception
* Refusal to participate in the study

Where it's running

  • CHRU de NANCY
    Vandœuvre-lès-Nancy, France
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.